Several FGFR3-targeted treatments for ACH have experimentally been applied in recent years, including C-type natriuretic peptide (CNP) [6], NVP-BGJ398 (specific inhibitor for FGFR3) [7], anti-FGF2 aptamer [8], soluble FGFR3 (decoy receptor for FGFR3) [9], and statins [10]. Here, FGFR3 is linked to achondroplasia.